Merck KGaA Opens Viral Clearance Lab in Shanghai’s Biologics Testing Center
German pharmaceutical giant Merck KGaA has opened a viral clearance (VC) laboratory as part of...
METiS Therapeutics In-Licenses Voronoi’s Pan-RAF Inhibitor Program
Cambridge, Massachusetts-based METiS Therapeutics has unveiled its first in-license deal, signing with South Korea’s Voronoi...
Heilongjiang Launches ‘Longjiang Huiminbao’ Supplementary Health Insurance Scheme
Heilongjiang province has launched its first provincial-level supplementary commercial health insurance scheme, branded “Longjiang Huiminbao.”...
Immuno Cure BioTech Acquires Majority Stake in Shanghai Teresa Healthcare
Hong Kong-based Immuno Cure BioTech has announced the acquisition of a controlling 92.6% stake in...
Lepu Biotechnology’s MRG003 Receives Orphan Drug Designation from FDA
China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received orphan drug...
Kamari Pharma Completes $8M Investment from Chinese Fund GIBF2
Israel-based Kamari Pharma has announced the completion of an $8 million investment from the Chinese...
Joincare’s Modified Drug XYP-001 Gains NMPA Approval for IPF Trial
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced that it has received...
Koutech Robotics Secures Series A Funding for Surgical Innovation
China-based Koutech Robotics (Shanghai) Co., Ltd, a leading ultra-micro, high-precision surgical robot platform company, has...
CARsgen Therapeutics Presents Positive Phase Ib/II Data for CT053 at CAR-TCR Summit
China-based CARsgen Therapeutics Holdings Ltd presented the results of a multi-center, open-label Phase Ib/II study...
Joincare Pharmaceuticals Prices GDRs on SIX Swiss Exchange
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has priced its Global Depository Receipts...
Northeast Pharmaceutical to Invest in Shanghai Subsidiary for ADC and CAR-T Development
China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has announced plans to invest RMB 500 million...
Beijing Designates 923 Medical Entities for National Reimbursement Drug List
The Beijing Municipal Medical Insurance Bureau has released a notification indicating that a total of...
Lee’s Pharmaceutical Reports H1 Revenue Growth Amid Product Portfolio Shift
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its H1 2022 interim financial report,...
Junshi Biosciences’ Tuoyi Approved for First-Line NSCLC Treatment in China
China’s Center for Drug Evaluation (CDE) has approved Junshi Biosciences’ (HKG: 1877, SHA: 688180) Tuoyi...
Sun-Novo’s STC007 Gains NMPA Approval for Postoperative Pain Study
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd has announced that it has received approval from...
WuXi Biologics Partners with Elpiscience for Macromolecule Development
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced multiple...
Tasly Pharmaceuticals Gains NMPA Approval for B1344 Diabetes Study
China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the National...
Clover Biopharmaceuticals Reports Positive Phase III Data for COVID-19 Vaccine SCB-2019
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has announced additional positive Phase III clinical trial data...
RemeGen Announces Positive Phase III Results for Telitacicept in SLE
China-based pharma firm RemeGen (HKG: 9995) has announced the conclusion of a Phase III confirmatory...
BeiGene’s Brukinsa Receives New EU and UK Indications for BTK Inhibitor
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has received two new indication...